Navigation Links
NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welch's
Date:9/17/2007

HUBBARD, Ohio, Sept. 17 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX), a nano-biotechnology company, announced it has achieved a historical event with the first onsite generation of electricity using hydrogen gas produced from its bioreactor prototype facility at Welch Foods Inc., a Cooperative in Pennsylvania.

A 5.5 kW generator converted to run on hydrogen was utilized for the demonstration. The generator ran flawlessly on hydrogen gas produced by NanoLogix's hydrogen bioreactor system and powered multiple strings of 100- watt light bulbs. "To the best of our knowledge, this is the first time in history that electricity has been generated anywhere onsite using hydrogen produced through the use of bacteria to digest waste", said Harry Diz, Department Chair and Professor of Environmental Engineering at Gannon University and NanoLogix Bioreactor Development chief. Video: http://www.youtube.com/watch?v=cS_jmMwy9D8

Paul Zorzie, Welch's Engineering Manager, stated, "Welch's is happy to provide the site at which this groundbreaking research into generating alternative energy from waste is taking place. We look forward to the potential of building upon these developments to scale up and use this energy for our operation."

Bret Barnhizer, Chairman and CEO of NanoLogix, stated, "We are delighted at the results of the work by Professor Diz and associates and anticipate potential upscaling of the Welch's operation to commercial bioreactor status. The Welch's development, enabling conversion of sugar from their wastewater stream to produce hydrogen, has contributed immeasurably to ongoing research and development for processing other types of waste streams. Linked to that development and following our business plan for expansion, in the spring of 2008 we intend to begin bioreactor construction at the Erie Wastewater Treatment Plant for the extraction of hydrogen from their protein-rich activated sludge waste stream."

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and 36 Patents Pending for bioreactor-based hydrogen production, revolutionary rapid medical testing technologies, potential treatments for sepsis and cancer, and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800

E-mail:Bret@nanologixinc.com


'/>"/>
SOURCE NanoLogix Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS ... precision treatments for neurodegenerative diseases, today announced it has issued a scientific white ... is one of a series of commentaries from ProMIS’s scientific team offering insight ...
(Date:2/22/2017)... 22, 2017 Origin (Origin Agritech, LLC, a subsidiary of ... provider, and Arcadia (Arcadia Biosciences, Inc., NASDAQ: ... commercializes agricultural productivity traits and nutritional products, today announced their collaboration ... developed in China to the ... ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, ... (OTCQB:CELZ) announced today expansion of its translational research ... product through establishment of laboratory facilities in San ... the San Diego BioLabs facility, a biotechnology incubator ... and Sanofi. In November 2016, the ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, CloudMine, ... applications, announced a partnership with Redox, a leader in cloud-based healthcare integration and ... systems while keeping data secure in the cloud. , The digital health developers, ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):